Clinical and pathological features predictive of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: We determined the clinical and pathological features associated with nephrectomy at post-chemotherapy retroperitoneal lymph node dissection. Materials and Methods: We retrospectively reviewed the testis cancer database from 1980 to 2007 to identify all patients treated with post-chemotherapy retroperitoneal lymph node dissection. Patients with pure seminoma and nongerm cell histology were excluded from study. A total of 1,807 patients were identified, of whom 17 without recorded mass size were excluded from further study. Pathological and clinical variables were assessed by bivariate analysis. Multivariate logistic regression was used to determine predictors of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection. Results: The overall incidence of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection was 14.8% (265 of 1,790 cases). The incidence of nephrectomy was 17.0%, 18.9%, 13.6% and 8.0% in 1980 to 1988 (group 1), 1989 to 1997 (group 2), 1998 to 2002 (group 3) and 2002 to 2007 (group 4) (p = 0.0001). The nephrectomy rate for tumors less than 2, 2 to 5, 5 to 10 and greater than 10 cm was 6.0%, 5.8%, 13.9% and 31.9%, respectively (p = 0.0001). The incidence of nephrectomy based on retroperitoneal histology was 10.3% for fibrosis, 14.5% for teratoma and 20.4% for cancer (p = 0.0001). The strongest predictor of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection was retroperitoneal mass size greater than 10 cm (OR 9.30, 95% CI 3.8-22.7). Conclusions: The incidence of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection has decreased in the last 3 decades. A higher incidence was observed in patients with larger volume tumors, those who received salvage chemotherapy, those with a left primary testicular tumor and those with increased markers at post-chemotherapy surgery.

Original languageEnglish
Pages (from-to)812-817
Number of pages6
JournalJournal of Urology
Volume189
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Lymph Node Excision
Nephrectomy
Drug Therapy
Incidence
Testicular Neoplasms
Histology
Seminoma
Teratoma
Tumor Burden
Neoplasms
Fibrosis
Logistic Models
Databases

Keywords

  • drug therapy
  • lymph node dissection
  • nephrectomy
  • testicular neoplasms
  • testis

ASJC Scopus subject areas

  • Urology

Cite this

@article{f473eaa3943a4a9a8682b3a74004086a,
title = "Clinical and pathological features predictive of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection",
abstract = "Purpose: We determined the clinical and pathological features associated with nephrectomy at post-chemotherapy retroperitoneal lymph node dissection. Materials and Methods: We retrospectively reviewed the testis cancer database from 1980 to 2007 to identify all patients treated with post-chemotherapy retroperitoneal lymph node dissection. Patients with pure seminoma and nongerm cell histology were excluded from study. A total of 1,807 patients were identified, of whom 17 without recorded mass size were excluded from further study. Pathological and clinical variables were assessed by bivariate analysis. Multivariate logistic regression was used to determine predictors of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection. Results: The overall incidence of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection was 14.8{\%} (265 of 1,790 cases). The incidence of nephrectomy was 17.0{\%}, 18.9{\%}, 13.6{\%} and 8.0{\%} in 1980 to 1988 (group 1), 1989 to 1997 (group 2), 1998 to 2002 (group 3) and 2002 to 2007 (group 4) (p = 0.0001). The nephrectomy rate for tumors less than 2, 2 to 5, 5 to 10 and greater than 10 cm was 6.0{\%}, 5.8{\%}, 13.9{\%} and 31.9{\%}, respectively (p = 0.0001). The incidence of nephrectomy based on retroperitoneal histology was 10.3{\%} for fibrosis, 14.5{\%} for teratoma and 20.4{\%} for cancer (p = 0.0001). The strongest predictor of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection was retroperitoneal mass size greater than 10 cm (OR 9.30, 95{\%} CI 3.8-22.7). Conclusions: The incidence of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection has decreased in the last 3 decades. A higher incidence was observed in patients with larger volume tumors, those who received salvage chemotherapy, those with a left primary testicular tumor and those with increased markers at post-chemotherapy surgery.",
keywords = "drug therapy, lymph node dissection, nephrectomy, testicular neoplasms, testis",
author = "Cary, {K. Clinton} and Beck, {Stephen D W} and Richard Bihrle and Richard Foster",
year = "2013",
month = "3",
doi = "10.1016/j.juro.2012.09.083",
language = "English",
volume = "189",
pages = "812--817",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical and pathological features predictive of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection

AU - Cary, K. Clinton

AU - Beck, Stephen D W

AU - Bihrle, Richard

AU - Foster, Richard

PY - 2013/3

Y1 - 2013/3

N2 - Purpose: We determined the clinical and pathological features associated with nephrectomy at post-chemotherapy retroperitoneal lymph node dissection. Materials and Methods: We retrospectively reviewed the testis cancer database from 1980 to 2007 to identify all patients treated with post-chemotherapy retroperitoneal lymph node dissection. Patients with pure seminoma and nongerm cell histology were excluded from study. A total of 1,807 patients were identified, of whom 17 without recorded mass size were excluded from further study. Pathological and clinical variables were assessed by bivariate analysis. Multivariate logistic regression was used to determine predictors of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection. Results: The overall incidence of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection was 14.8% (265 of 1,790 cases). The incidence of nephrectomy was 17.0%, 18.9%, 13.6% and 8.0% in 1980 to 1988 (group 1), 1989 to 1997 (group 2), 1998 to 2002 (group 3) and 2002 to 2007 (group 4) (p = 0.0001). The nephrectomy rate for tumors less than 2, 2 to 5, 5 to 10 and greater than 10 cm was 6.0%, 5.8%, 13.9% and 31.9%, respectively (p = 0.0001). The incidence of nephrectomy based on retroperitoneal histology was 10.3% for fibrosis, 14.5% for teratoma and 20.4% for cancer (p = 0.0001). The strongest predictor of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection was retroperitoneal mass size greater than 10 cm (OR 9.30, 95% CI 3.8-22.7). Conclusions: The incidence of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection has decreased in the last 3 decades. A higher incidence was observed in patients with larger volume tumors, those who received salvage chemotherapy, those with a left primary testicular tumor and those with increased markers at post-chemotherapy surgery.

AB - Purpose: We determined the clinical and pathological features associated with nephrectomy at post-chemotherapy retroperitoneal lymph node dissection. Materials and Methods: We retrospectively reviewed the testis cancer database from 1980 to 2007 to identify all patients treated with post-chemotherapy retroperitoneal lymph node dissection. Patients with pure seminoma and nongerm cell histology were excluded from study. A total of 1,807 patients were identified, of whom 17 without recorded mass size were excluded from further study. Pathological and clinical variables were assessed by bivariate analysis. Multivariate logistic regression was used to determine predictors of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection. Results: The overall incidence of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection was 14.8% (265 of 1,790 cases). The incidence of nephrectomy was 17.0%, 18.9%, 13.6% and 8.0% in 1980 to 1988 (group 1), 1989 to 1997 (group 2), 1998 to 2002 (group 3) and 2002 to 2007 (group 4) (p = 0.0001). The nephrectomy rate for tumors less than 2, 2 to 5, 5 to 10 and greater than 10 cm was 6.0%, 5.8%, 13.9% and 31.9%, respectively (p = 0.0001). The incidence of nephrectomy based on retroperitoneal histology was 10.3% for fibrosis, 14.5% for teratoma and 20.4% for cancer (p = 0.0001). The strongest predictor of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection was retroperitoneal mass size greater than 10 cm (OR 9.30, 95% CI 3.8-22.7). Conclusions: The incidence of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection has decreased in the last 3 decades. A higher incidence was observed in patients with larger volume tumors, those who received salvage chemotherapy, those with a left primary testicular tumor and those with increased markers at post-chemotherapy surgery.

KW - drug therapy

KW - lymph node dissection

KW - nephrectomy

KW - testicular neoplasms

KW - testis

UR - http://www.scopus.com/inward/record.url?scp=84873723214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873723214&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2012.09.083

DO - 10.1016/j.juro.2012.09.083

M3 - Article

C2 - 23017517

AN - SCOPUS:84873723214

VL - 189

SP - 812

EP - 817

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -